Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'

Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on patient eligibility. He speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)